Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Genital Herpes Pipeline Insight

DelveInsight’s, “Genital Herpes – Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Genital Herpes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.  

Geography Covered

  • Global coverage

Genital Herpes Understanding

Genital Herpes: Overview

Herpes genitalis is among the most common sexually transmitted infections. It is caused by the herpes simplex virus type 2 (HSV-2) and also, increasingly, the herpes simplex virus type 1 (HSV-1). Both organisms are enveloped DNA viruses that are sensitive to disinfectants and environmental factors 1. Due to marked genetic homology between HSV-1 and HSV-2 numerous biological similarities and antigenic cross-reactions between the viruses exist. The first signs of genital herpes usually show up two to 12 days after having sexual contact with someone who has herpes. Symptoms can last from two to four weeks. There are other early symptoms of genital herpes: Feeling of pressure in the abdomen, Flu-like symptoms, including fever, Itching or burning feeling in the genital or anal area, Pain in the legs, buttocks, or genital area, Swollen glands, and Unusual vaginal discharge. The laboratory diagnosis of acute genital HSV infection or asymptomatic virus shedding is made via direct viral detection. The method of choice is demonstration of viral genomes in skin or mucous membrane swabs using the polymerase chain reaction (PCR). Standard first-line drugs include acyclovir, valacyclovir and famciclovir. The specific antiviral action of these acyclic nucleoside analogues is based on their phosphorylation to monophosphate form by thymidine kinase (TK), the key enzyme of HSV-1 and HSV-2, with subsequent phosphorylation via di- to triphosphate form by cellular enzymes.


"Genital Herpes - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Genital Herpes pipeline landscape is provided which includes the disease overview and Genital Herpes treatment guidelines. The assessment part of the report embraces, in depth Genital Herpes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Genital Herpes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Genital Herpes R&D. The therapies under development are focused on novel approaches to treat/improve Genital Herpes.

Genital Herpes Emerging Drugs Chapters

This segment of the Genital Herpes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Genital Herpes Emerging Drugs


Pritelivir: AiCuris

Pritelivir is a new small molecule, a helicase-primase inhibitor with a novel mode of action. The drug is in phase III stage of development for the treatment of Genital Herpes. Pritelivir has a mode of action that is distinct from other antiviral agents currently in use for treating HSV infections (i.e., the nucleoside analogs acyclovir and its prodrug valacyclovir as well as famciclovir, the prodrug of penciclovir). While nucleoside analogs terminate ongoing DNA chain elongation through inhibition of viral DNA polymerase, pritelivir prevents de novo synthesis of viral DNA through inhibition of the helicase-primase complex. In addition, it does not require activation within an HSV infected cell by viral thymidine kinase and is therefore also protective to uninfected cells. In June 2020, AiCuris was granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the treatment of HSV infections in immunocompromised patients.


UB-621: United Biopharma

UB-621 is a human IgG1 monoclonal antibody that targets conserved gD protein of Herpes simplex virus (HSV) type I and type II. The drug is in phase II stage of development for the treatment of Genital Herpes. It has been shown in vitro to block HSV infections of both wild type and acyclovir-resistant viral strains with over hundreds-fold higher potency.


HDIT 101: Heidelberg ImmunoTherapeutics

HDIT 101, a humanized monoclonal antibody is being developed by Heidelberg ImmunoTherapeutics GmbH for the treatment of human herpes simplex virus (HSV) infections. The drug is currently in phase II stage of development for the treatment of Genital Herpes.

Further product details are provided in the report……..

Genital Herpes: Therapeutic Assessment

This segment of the report provides insights about the different Genital Herpes drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Genital Herpes

There are approx. 25+ key companies which are developing the therapies for Genital Herpes. The companies which have their Genital Herpes drug candidates in the most advanced stage, i.e. Phase III include, AiCuris.

Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Genital Herpes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Genital Herpes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Genital Herpes therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Herpes drugs.

Genital Herpes Report Insights

  • Genital Herpes Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Genital Herpes Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Genital Herpes drugs?
  • How many Genital Herpes drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Genital Herpes?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Genital Herpes therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Genital Herpes and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Genital Herpes: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

Pritelivir: AiCuris

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

UB-621: United Biopharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early stage products (Phase I/II)

  • Comparative Analysis

HSV 2 Vaccines: Sanofi

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Genital Herpes Key Companies

Genital Herpes Key Products

Genital Herpes- Unmet Needs

Genital Herpes- Market Drivers and Barriers

Genital Herpes- Future Perspectives and Conclusion

Genital Herpes Analyst Views

Genital Herpes Key Companies

Appendix

List of Table

Table 1: Total Products for Genital Herpes

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Genital Herpes

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products   

• Immune System Regulation

• United BioPharma

• Heidelberg ImmunoTherapeutics

• Genocea Biosciences

• AiCuris

• Admedus Immunotherapies

• Agenus Inc.

• Sanofi

• Rational Vaccines

• Starpharma

• Brandenburg Antiinfektiva GmbH

• JN-International Medical Corporation

• BlueWillow Biologics

• Vaxxit

• Nanoviricides

• Vaccibody

• Vaxart

• Biomere

• Immune design (acquired by Merck & Co)

• AlphaVax

• RedBioTec

• X-Vax Technology

Forward to Friend

Need A Quote